Literature DB >> 8987247

Reactive metabolites and agranulocytosis.

J P Uetrecht1.   

Abstract

Central to most hypotheses of the mechanism of idiosyncratic drug-induced blood dyscrasias is the involvement of reactive metabolites. In view of the reactive nature of the majority of such metabolites, it is likely that they are formed by, or in close proximity to the blood cells affected. The major oxidative system of neutrophils generates hypochlorous acid. We have demonstrated that the drugs associated with the highest incidence of agranulocytosis are oxidized to reactive metabolites by hypochlorous acid and/or activated neutrophils. There are many mechanisms by which such reactive metabolites could induce agranulocytosis. In the case of aminopyrine-induced agranulocytosis, most cases appear to involve drug-dependent anti-neutrophil antibodies, and these are likely to be induced by cell membrane antigens modified by the reactive metabolite of aminopyrine. The target of agranulocytosis associated with many other drugs is usually neutrophil precursors and may involve cytotoxicity or a cell-mediated immune reaction induced by a reactive metabolite. In the case of aplastic anaemia, there is evidence in some cases for involvement of cytotoxic T cells, which could either be induced by metabolites generated by neutrophils, or more likely, by reactive metabolites generated by stem cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8987247     DOI: 10.1111/j.1600-0609.1996.tb01651.x

Source DB:  PubMed          Journal:  Eur J Haematol Suppl        ISSN: 0902-4506


  6 in total

1.  Ceftobiprole associated agranulocytosis after drug rash with eosinophilia and systemic symptoms induced by vancomycin and rifampicin.

Authors:  Thomas Wendland; Barbara Daubner; Werner J Pichler
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

2.  [Dapsone-induced agranulocytosis. The role of xenobiotic-metabolizing enzymes demonstrated by a case report].

Authors:  T K Hoffmann; S von Schmiedeberg; M Wulferink; R Thier; H Bier; T Ruzicka; P Lehmann
Journal:  Hautarzt       Date:  2005-07       Impact factor: 0.751

Review 3.  [Dipyrone (metamizole) : Considerations on monitoring for early detection of agranulocytosis].

Authors:  U M Stamer; U Gundert-Remy; E Biermann; J Erlenwein; W Meiβner; S Wirz; T Stammschulte
Journal:  Schmerz       Date:  2017-02       Impact factor: 1.107

4.  Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012.

Authors:  Thomas Stammschulte; Wolf-Dieter Ludwig; Bernd Mühlbauer; Elisabeth Bronder; Ursula Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  2015-07-15       Impact factor: 2.953

Review 5.  Felbamate in epilepsy therapy: evaluating the risks.

Authors:  J M Pellock
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

6.  [Perioperative use of metamizole and other nonopioid analgesics in children : Results of a survey].

Authors:  L Witschi; L Reist; T Stammschulte; J Erlenwein; K Becke; U Stamer
Journal:  Anaesthesist       Date:  2019-01-24       Impact factor: 1.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.